×

Do you want to link to this External Site and leave Amgen.com.sg?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this Amgen website and leave Amgen.com.sg?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Singapore takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Singapore Manufacturing Capabilities

Amgen Singapore Manufacturing is a truly unique biotechnology pioneer. We have groundbreaking manufacturing facilities built using state-of-the-art science, incorporating highly sustainable and flexible processes and a strong pipeline.

On 20 November 2014, Amgen inaugurated its revolutionary Next-Generation Biomanufacturing facility in Tuas Biomedical Park, marking the company's first manufacturing site in Asia. It is built with a state-of-the-art modular and reconfigurable design that can be replicated in future facilities.

Constructed in a short time frame of 15 months with only a quarter of the capital cost, this Next-Generation Biomanufacturing facility comes with a highly sustainable environmental footprint; using approximately 80% less energy and water with a 75% reduction in carbon dioxide emission levels. The Singapore facility is still able to deliver the same quantity of products, while its size is 75% smaller than a conventional facility.

A second facility at the same site is well on its way to completing development and will be responsible for large chemical synthesis manufacturing. This new facility will be Amgen’s first commercial Active Pharmaceutical Ingredient (API) facility.

The Singapore Next-Generation Biomanufacturing facility uses a number of innovative technologies to produce denosumab, which is formulated into the medicines Prolia® and XGEVA® to treat osteoporosis and bone-related disorders in cancer patients. The second facility will produce carfilzomib, the active pharmaceutical ingredient for Kyprolis® to treat multiple myeloma.

At Amgen Singapore Manufacturing, we constantly invest in our manufacturing capabilities to deliver products of superior quality and sophistication to further strengthen our proficiencies and capabilities. Home to more than 250 people, we constantly support and empower our people to draw the link between disease, science and patient care. In doing so, we are able to provide greater accessibility to our medicines and best serve patients around the world.

Manufacturing

Amgen Singapore’s Next-Generation Bio manufacturing facility located in Tuas Biomedical Park.

Singapore Staff

Encompassing a pioneering and entrepreneurial spirit, our employees work in a team-based environment that fosters a culture of inclusion, respect and responsibility.